ARNA Key Statistics, Chart & Performance
The current stock price of ARNA is 99.99 null. In the past month the price increased by 7.01%. In the past year, price increased by 29.74%.
ARNA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ARNA. When comparing the yearly performance of all stocks, ARNA is one of the better performing stocks in the market, outperforming 98.23% of all stocks.
ARNA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ARNA. ARNA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ARNA Financial Highlights
Over the last trailing twelve months ARNA reported a non-GAAP Earnings per Share(EPS) of -8.84. The EPS decreased by -19.46% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -1141511.11% | ||
| ROA | -78.55% | ||
| ROE | N/A | ||
| Debt/Equity | 0.05 |
ARNA Forecast & Estimates
19 analysts have analysed ARNA and the average price target is 99.8 null. This implies a price decrease of -0.19% is expected in the next year compared to the current price of 99.99.
For the next year, analysts expect an EPS growth of 2.6% and a revenue growth 4629.54% for ARNA
ARNA Ownership
ARNA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.65 | 378.29B | ||
| AMGN | AMGEN INC | 15.13 | 178.24B | ||
| GILD | GILEAD SCIENCES INC | 15.16 | 154.02B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.47 | 112.16B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 77.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 697.12 | 46.97B | ||
| INSM | INSMED INC | N/A | 34.87B | ||
| NTRA | NATERA INC | N/A | 32.41B | ||
| BIIB | BIOGEN INC | 9.88 | 24.26B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.47B | ||
| INCY | INCYTE CORP | 15.98 | 20.15B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.74 | 20.16B |
Related stock screener links
About ARNA
Company Profile
Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protien-coupled receptors. The company is headquartered in San Diego, California and currently employs 448 full-time employees. The company went IPO on 2000-07-28. The firm's clinical programs include Etrasimod, which is an oral, selective sphingosine 1-phosphate (S1P), receptor modulator, designed to provide systemic and local cell modulation by targeting S1P receptor subtypes one, four and five. Olorinab, an orally available, potent, peripherally acting, selective, full agonist of the CB2 receptor, is an internally discovered investigational drug candidate. APD418 is an adrenergic receptor (AdrR) antagonist and cardiac myotrope designed to regulate myofilament calcium sensitivity in order to improve contractility without inducing the adverse events associated with available inotropes. Temanogrel is a peripherally acting and selective 5HT2a inverse agonist designed to inhibit serotonin (5-HT) mediated amplification of platelet aggregation and vasoconstriction.
Company Info
ARENA PHARMACEUTICALS INC
6154 Nancy Ridge Dr
San Diego CALIFORNIA 92121 US
CEO: Amit D. Munshi
Employees: 448
Phone: 18584537200.0
ARENA PHARMACEUTICALS INC / ARNA FAQ
Can you describe the business of ARENA PHARMACEUTICALS INC?
Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protien-coupled receptors. The company is headquartered in San Diego, California and currently employs 448 full-time employees. The company went IPO on 2000-07-28. The firm's clinical programs include Etrasimod, which is an oral, selective sphingosine 1-phosphate (S1P), receptor modulator, designed to provide systemic and local cell modulation by targeting S1P receptor subtypes one, four and five. Olorinab, an orally available, potent, peripherally acting, selective, full agonist of the CB2 receptor, is an internally discovered investigational drug candidate. APD418 is an adrenergic receptor (AdrR) antagonist and cardiac myotrope designed to regulate myofilament calcium sensitivity in order to improve contractility without inducing the adverse events associated with available inotropes. Temanogrel is a peripherally acting and selective 5HT2a inverse agonist designed to inhibit serotonin (5-HT) mediated amplification of platelet aggregation and vasoconstriction.
What is the stock price of ARENA PHARMACEUTICALS INC today?
The current stock price of ARNA is 99.99 null. The price increased by 0.06% in the last trading session.
Does ARENA PHARMACEUTICALS INC pay dividends?
ARNA does not pay a dividend.
What is the ChartMill technical and fundamental rating of ARNA stock?
ARNA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of ARENA PHARMACEUTICALS INC (ARNA)?
ARENA PHARMACEUTICALS INC (ARNA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-8.84).
Would investing in ARENA PHARMACEUTICALS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ARNA.